Media

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]

Sort by Year

December 17, 2012

Ironwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide)

December 6, 2012

Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration

November 28, 2012

Constella® (linaclotide) Approved in Europe for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

November 9, 2012

Ironwood Pharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference

November 1, 2012

Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS™ (Linaclotide)

October 23, 2012

Ironwood and AstraZeneca Announce Linaclotide Collaboration for China

October 16, 2012

Ironwood Pharmaceuticals Provides Third Quarter 2012 Investor Update

October 9, 2012

Ironwood Pharmaceuticals to Host Third Quarter 2012 Investor Update Call

September 21, 2012

Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C

September 12, 2012

Ironwood Pharmaceuticals to Present at the UBS Global Life Sciences Conference

September 6, 2012

Ironwood Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

August 30, 2012

Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESS™ (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

August 30, 2012

Ironwood and Forest Announce FDA Approval of LINZESS™ (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

July 17, 2012

Ironwood Pharmaceuticals Provides Second Quarter 2012 Investor Update

July 10, 2012

Ironwood Pharmaceuticals to Host Second Quarter 2012 Investor Update Call